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Summary.-Gonadotrophins, oestradiol, androstenedione, testosterone and dehydro-
epiandrosterone sulphate (DHAS) were measured sequentially in 72 patients with
advanced breast cancer receiving endocrine therapy of various types. Tamoxifen
significantly reduced gonadotrophins but did not effect other hormones. Danazol also
reduced gonadotrophins. Aminoglutethimide (AGT) reduced oestradiol and DHAS
but had no effect on gonadotrophins. The effects of administering tamoxifen, AGT
and danazol together (TAD) together were therefore examined. This combination
reduced gonadotrophins, oestradiol and DHAS, but no further than tamoxifen and
AGT alone.
The degree and duration of hormone suppression were similar in both responders
and non-responders to tamoxifen, AGT or TAD, though patients responding to AGT
showed more complete suppression at the end of the course of treatment, perhaps
because they were treated longer. On relapse, adequate gonadotrophin and steroid
suppression was demonstrated in patients receiving tamoxifen and AGT respectively.
We conclude that (a) response to endocrine therapy is unlikely to be related to the
degree of endocrine suppression produced by the therapy; (b) combination endocrine
therapy does not further reduce serum-hormone concentrations and (c) relapse
is unlikely to be due to escape from the hormone-inhibitory effects of endocrine
agents.
ENDOCRINE THERAPY is an effective
form of treatment in patients with ad-
vanced breast cancer. However, only a
proportion of patients respond, and their
response is often transient. Patients whose
tumours contain a high concentration of
oestrogen receptor are more likely to
respond to endocrine therapy (McGuire et
al., 1975) but a moderate proportion of
patients whose tumours contain receptor
do not respond, and it may be that in
these patients inadequate hormone sup-
pression by endocrine therapy is respon-
sible for lack ofeffect in these patients.
Few studies have been carried out to
elucidate the mechanism of relapse. It is
not known whether endocrine therapy is
still effective at the time of relapse, nor
whether relapse is due to premature
inactivation of endocrine agents. Studies
from our unit have indicated that relapse
is not often due to proliferation of an
oestrogen-receptor negative (RE-) cell
population, since most relapsing tumours
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contain significant quantities of RE (Tay-
lor et al., 1982). We therefore examined
whether relapse or non-response was due
to an inadequate effect of endocrine
agents on gonadotrophins and steroid
hormones in patients treated with tamoxi-
fen, aminoglutethimide (AGT) and dana-
zol, all of which are effective endocrine
agents (Ward, 1973; Smith et al., 1978;
Coombes et al., 1980a) and are known to
lower hormone concentrations (Golder et
al., 1976; Santen et al., 1977; Franchi-
mont & Cramilion, 1977).
PATIENTS, MATERIALS AND METHODS
Patients and therapy.-Samples were ob-
tained from 72 postmenopausal patients
with locally advanced or metastatic breast
cancer. No patient had received endocrine
therapy or chemotherapy within 3 weeks of
the start of therapy. Hormones were meas-
ured at 2-3 months and 6-12 months or, in
the case of patients who failed to respond, at
4-6 months after starting therapy.
In 18 patients who had responded to
endocrine therapy, serum samples were
obtained at the time of relapse. All these
patients were still taking endocrine therapy
at the time of sampling.
Patients received tamoxifen (Nolvadex:
ICI) 10 mg twice daily (24 patients), danazol
(Danol: Sterling-Winthrop) 200 mg 3 x daily
(12 patients) oraminoglutethimide (Orimeten:
Ciba) 250 mg 4 x daily (16 patients). Amino-
glutethimide was administered with hydro-
cortisone (20 mg twice daily).
Nineteen patientsreceived a combination of
tamoxifen, danazol and AGT with hydro-
cortisone supplements (TAD).
Hormone measurements.-Blood was ob-
tained from non-fasting patients, separated
within 30 min, and plasma and serum stored
at -70°C until assay.
Androstenedione and oestradiol were meas-
ured in serum extracts by conventional
immunoassays, and between-batch coeffici-
ents of variation (CV) were 15 and 12.5%
respectively. Testosterone was assayed in
serum extracts using a 125J-radioligand with
separation by a double-antibody method, and
the between-batch CV was 11%. Danazol was
shown to cross-react in the testosterone
assay, and the magnitude of this interference
would depend on therapeutic levels of
Danazol. DHAS was assayed in unextracted
serum, with separation by a double-antibody
method, and the between-batch CV was 13%.
Serum LH and FSH was measured by
radioimmunoassay using MRC standards
68/40 for LH and 69/104 for FSH, and anti-
sera F87 and M93 kindly provided by
Professor W. Butt. All assays were quality
controlled on the Supra-regional Assay
Service, Quality Control System.
Assessment.-Full staging investigations
(Coombes et al., 1980b) were carried out
before, and at 2-3-monthly intervals during
therapy.
Assessment of response was carried out
using standard UICC criteria (Hayward et al.,
1977).
RESULTS
Tamoxifen
Tamoxifen reduced FSH and LH in
40143 patients after 2 months oftherapy,
and this suppression continued to 9-12
months in all patients. No effects were
seen on other hormones. The addition of
AGT and danazol did not further reduce
the gonadotrophins (Table; Fig. 1).
Gonadotrophin suppression was still
found to be effective in the 7 patients in
whom hormones were measured at relapse
following response (serum LH= 13-38
iu/l (mean 24.3) and serum FSH= 13-26
iu/l (mean 19.9).
Aminoyltutethimide
AGT caused a reduction in plasma
DHAS and oestradiol in all patients in
whom these hormones were measurable at
the start oftherapy (Table). More respond-
ers than non-responders showed a con-
tinued almost complete suppression of
DHAS, and DHASvalueswere 0-046 + 0*03
-M (n = 8) and 0-25 + 0-09tM (n= 6)respec-
tivelybutnon-responders receivedtherapy
for an average of 3-5 months, compared
with responders who received treatment
for 9.75 months (Fig. 1). The addition of
tamoxifen anddanazol, whilstsignificantly
reducing gonadotrophins, did not further
reduce plasma DHAS or oestrogen (Fig. 1;
Table).
DHAS was measured up to and at the
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FiG. 1. Serum DHAS in responders (-
and non-responders ( ) during treat-
ment with aminoglutethimide (left) and
tamoxifen, aminoglutethimide and danazol
(right).
time of relapse in 8 patients treated with
AGT alone, and in a further 4 patients
treated with TAD combination, and
levels of DHAS were still undetectable in
all but one patient. No significant effect on
any other hormone was seen.
Danazol
Danazol suppressed gonadotrophins in
10/12 patients (Table) but effects on
steroid hormones were inconsistent.
Marked rises in testosterone were seen in
6 patients but not in others. Similarly,
marked falls in DHAS were seen in 4/12
patients, but not in others. The rises in
testosterone were difficult to evaluate in
view of possible danazol cross-reactivity
in the assay.
Insufficient numbers of patients were
monitored to determine whether there
was a relationship between degree of
gonadotrophin suppression and response.
TAD combination
This reduced gonadotrophins to a simi-
lar extent to tamoxifen alone, and also in
responders and non-responders (Fig. 2).
Suppression continued until 9-12 months
of relapse in the 6 patients measured at
relapse (Table; Fig. 2).
Suppression by the TAD combination
was similar to patients receiving AGT
alone.
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FIG. 2.-Serum LH in responders (-----) and
non-responders ( ) during treatment
with tamoxifen (left) and tamoxifen,
aminoglutethimide and danazol (right).
Similar results were obtained with measure-
ments ofFSH.
DISCUSSION
The major measurable effect of tamoxi-
fen was found to be suppression of
gonadotrophins, and that of AGT was
suppression of DHAS. It was for this
reason that we examined these compounds
in greater detail in relation to outcome of
therapy. In general there was no difference
in the extent to which hormones were
suppressed by these agents in responders
and non-responders to therapy. Respond-
ers to AGT alone appeared to show a more
complete suppression of DHAS, but this
was only demonstrated at the end of
treatment, and could have been due to a
longer course of therapy. Suppression of
hormones appeared to continue as long as
the course of therapy, even when the
patient relapsed. Insufficient numbers of
patients were treated with danazol to
establish whether relapse with danazol
therapy is due to failure of drug action,
and further studies are currently in
progress to determine whether this is so.
Relapse or non-response following endo-
crine therapy is therefore unlikely to be
related to inadequate suppression of
steroid hormones or gonadotrophins,
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though complete hormone suppression of
oestrogens has not been demonstrated,
mainly due to insufficiently sensitive
assays. Thus, although suppression of
oestradiol and oestrone are likely to be the
most important effects of AGT therapy,
the former is difficult to measure in
postmenopausal women due to lack of
adequate sensitivity, and the levels of
oestrone are affected by imbalanced hepa-
tic function, invalidating this assay in
patients with hepatic metastases (M.
Dowsett, personal communication). We
have therefore measured drug action
indirectly, by quantitating DHAS sup-
pression which is a measure of the steroid
C-20 and 22 hydroxylase-desmolase en-
zyme system. It appears that adequate
suppression still operates on relapse.
Similarly, the effect of tamoxifen on
gonadotrophin concentrations is likely to
be a secondary effect, since it is known
that the major site of action ofthe drug is
on RE (Jordan & Dowse, 1976). However,
we have demonstrated that after tamoxi-
fen therapy, the tumour is RE- (Taylor et
al., in press), suggesting that tamoxifen is
still capable ofbinding to RE on relapse or
non-response.
Relapse is therefore almost certainly
due to an inherent property of cancer cells
which enables them to regrow in an
initially unfavourable endocrine environ-
ment. Further studies are being carried
out to determine the other changes that
may be responsible for relapse in these
patients.
We thank Ms M. Abbott for technical help and the
surgeons and radiotherapists of The Royal Marsden
Hospital for permission to study their patients.
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